Clinical trial
A Phase II/III Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Visual Field Sensitivity as the Primary Outcome
NCT00447980 is registered in ClinicalTrials.gov with Neurotech Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II/III Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Visual Field Sensitivity as the Primary Outcome
- Lead sponsor
- Neurotech Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 22, 2007
- Completion date
- April 19, 2010
- Enrollment
- 73 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.